Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients

European Journal of Clinical Pharmacology

Volumn 67, Issue 3, 2011, Pages 253-260

  Berge, Maud ^a,b   Guillemain, Romain ^b   Trégouet, David A ^c   Amrein, Catherine ^b   Boussaud, Veronique ^b   Chevalier, Patrick ^b   Lillo Lelouet, Agnes ^b   Le Beller, Christine ^b   Laurent Puig, Pierre ^a,b,c   Beaune, Philippe H ^a,b,c   Billaud, Eliane M ^a,b   Loriot, Marie Anne ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c INSERM   (France)

Author keywords

CYP2C19 genotype; Cystic fibrosis; Lung transplantation; Voriconazole

Indexed keywords

ANTIBIOTIC AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIVIRUS AGENT; CYCLOSPORIN; CYTOCHROME P450 2C19; ESOMEPRAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID; OMEPRAZOLE; PANCREAS ENZYME; PANTOPRAZOLE; RABEPRAZOLE; STEROID; TACROLIMUS; VITAMIN; VORICONAZOLE;

ADOLESCENT; ADULT; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG RESPONSE; DRUG SAFETY; FEMALE; GENETIC VARIABILITY; GENOTYPE; GRAFT RECIPIENT; HETEROZYGOTE; HUMAN; LOADING DRUG DOSE; LUNG ASPERGILLOSIS; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAINTENANCE DRUG DOSE; MALE; NEUROMUSCULAR DISEASE; PHOTOSENSITIVITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNSPECIFIED SIDE EFFECT; WILD TYPE;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASPERGILLOSIS; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HUMANS; LUNG TRANSPLANTATION; MALE; PYRIMIDINES; RETROSPECTIVE STUDIES; TRIAZOLES; YOUNG ADULT;

EID: 79954442063     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0914-2     Document Type: Article

References (36)

1. R Herbrecht DW Denning TF Patterson, et al. 2002 Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Engl J Med 347 408 415 1:CAS:528:DC%2BD38XlvFKrt7o%3D 10.1056/NEJMoa020191 12167683 (Pubitemid 34851833)
2. TJ Walsh EJ Anaissie DW Denning, et al. 2008 Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America Clin Infect Dis 46 327 360 1:CAS:528:DC%2BD1cXitlKqt7c%3D 10.1086/525258 18177225 (Pubitemid 351265310)
3. J Smith D Andes 2008 Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations Ther Drug Monit 30 167 172 1:CAS:528:DC%2BD1cXjslSqtb8%3D 10.1097/FTD.0b013e318167d0e0 18367976 (Pubitemid 351521643)
4. A Pascual T Calandra S Bolay T Buclin J Bille O Marchetti 2008 Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes Clin Infect Dis 46 201 211 1:CAS:528:DC%2BD1cXhvVClsbY%3D 10.1086/524669 18171251 (Pubitemid 351269158)
5. GL Kearns WR Crom KH Karlson Jr GB Mallory Jr WE Evans 1996 Hepatic drug clearance in patients with mild cystic fibrosis Clin Pharmacol Ther 59 529 540 1:CAS:528:DyaK28XjvFOktbs%3D 10.1016/S0009-9236(96)90181-2 8646824 (Pubitemid 26191375)
6. E Rey JM Treluyer G Pons 1998 Drug disposition in cystic fibrosis Clin Pharmacokinet 35 313 329 1:CAS:528:DyaK1cXnsVWrs74%3D 10.2165/00003088- 199835040-00004 9812180 (Pubitemid 28491216)
7. J Prandota 1988 Clinical pharmacology of antibiotics and other drugs in cystic fibrosis Drugs 35 542 578 1:STN:280:DyaL1c3otlequw%3D%3D 10.2165/00003495-198835050-00004 3293970
8. Y Ikeda K Umemura K Kondo K Sekiguchi S Miyoshi M Nakashima 2004 Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status Clin Pharmacol Ther 75 587 588 1:CAS:528:DC%2BD2cXkslWmt7k%3D 10.1016/j.clpt.2004.02. 002 15179414 (Pubitemid 38746611)
9. M Kimura I Ieiri K Mamiya A Urae S Higuchi 1998 Genetic polymorphism of cytochrome P450s, CYP2C19 and CYP2C9 in a Japanese population Ther Drug Monit 20 243 247 1:CAS:528:DyaK1cXjvVChs7k%3D 10.1097/00007691-199806000-00001 9631918 (Pubitemid 28248841)
10. SC Sim C Risinger ML Dahl, et al. 2006 A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants Clin Pharmacol Ther 79 103 113 1:CAS:528:DC%2BD28XksVGltw%3D%3D 10.1016/j.clpt.2005.10.002 16413245 (Pubitemid 43069582)
11. G Wang HP Lei Z Li, et al. 2009 The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers Eur J Clin Pharmacol 65 281 285 1:CAS:528:DC%2BD1MXitVyiu7s%3D 10.1007/s00228-008-0574-7 18982321
12. R Hyland BC Jones DA Smith 2003 Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole Drug Metab Dispos 31 540 547 1:STN:280:DC%2BD3s7psF2mtQ%3D%3D 10.1124/dmd.31.5.540 12695341 (Pubitemid 36444162)
13. V Hafner N Albermann WE Haefeli F Ebinger 2008 Inhibition of voriconazole metabolism by chloramphenicol in an adolescent with central nervous system aspergillosis Antimicrob Agents Chemother 52 4172 4174 1:CAS:528: DC%2BD1cXhtlCgs7bE 10.1128/AAC.00805-08 18794387
14. P Liu G Foster RR LaBadie MJ Gutierrez A Sharma 2008 Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects J Clin Pharmacol 48 73 84 1:CAS:528:DC%2BD1cXhtVGqtL4%3D 10.1177/0091270007309703 18025525 (Pubitemid 350292275)
15. I Scholz H Oberwittler KD Riedel, et al. 2009 Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype Br J Clin Pharmacol 68 906 915 1:CAS:528: DC%2BC3cXkvFOqsA%3D%3D 10.1111/j.1365-2125.2009.03534.x 20002085
16. HJ Johnson K Han B Capitano, et al. 2010 Voriconazole pharmacokinetics in liver transplant recipients Antimicrob Agents Chemother 54 852 1:CAS:528:DC%2BC3cXhvFShsr8%3D 10.1128/AAC.00429-09 19933807
17. MO Karlsson I Lutsar PA Milligan 2009 Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies Antimicrob Agents Chemother 53 935 944 1:CAS:528:DC%2BD1MXivF2ltbk%3D 10.1128/AAC.00751-08 19075073
18. MJ Geist G Egerer J Burhenne G Mikus 2006 Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype Antimicrob Agents Chemother 50 3227 3228 1:CAS:528:DC%2BD28XpsFemsbg%3D 10.1128/AAC.00551-06 16940139 (Pubitemid 44396448)
19. C Eiden H Peyrière M Cociglio, et al. 2007 Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database Ann Pharmacother 41 755 763 1:CAS:528:DC%2BD2sXlvFyrsb4%3D 10.1345/aph.1H671 17456542 (Pubitemid 46752655)
20. J Cadena DJ Levine LF Angel, et al. 2009 Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness Am J Transplant 9 2085 2091 1:CAS:528:DC%2BD1MXht1ansrnO 10.1111/j.1600-6143.2009.02734.x 19645709
21. B Bégaud JC Evreux J Jouglard G Lagier 1985 Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France Therapie 40 111 118 4002188
22. GJ Pennick M Clark DA Sutton MG Rinaldi 2003 Development and validation of a high-performance liquid chromatography assay for voriconazole Antimicrob Agents Chemother 47 2348 2350 1:CAS:528:DC%2BD3sXltFehtbk%3D 10.1128/AAC.47.7.2348-2350.2003 12821496 (Pubitemid 36753600)
23. L Purkins N Wood P Ghahramani K Greenhalgh MJ Allen D Kleinermans 2002 Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens Antimicrob Agents Chemother 46 2546 2553 1:CAS:528:DC%2BD38XlsFGit7g%3D 10.1128/AAC.46.8.2546-2553.2002 12121931 (Pubitemid 34793462)
24. S Trifilio R Ortiz G Pennick Verma, et al. 2005 Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients Bone Marrow Transplant 35 509 513 1:CAS:528:DC%2BD2MXhsFWlsLs%3D 10.1038/sj.bmt.1704828 15654347 (Pubitemid 40403355)
25. M Berge R Guillemain V Boussaud, et al. 2009 Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients Transpl Infect Dis 11 211 219 1:STN:280:DC%2BD1MrhsVyktQ%3D%3D 10.1111/j.1399-3062.2009.00384.x 19302272
26. Z Desta X Zhao JG Shin DA Flockhart 2002 Clinical significance of the cytochrome P450 2C19 genetic polymorphism Clin Pharmacokinet 41 913 958 1:CAS:528:DC%2BD38XotlGisbg%3D 10.2165/00003088-200241120-00002 12222994 (Pubitemid 35168437)
27. J Weiss MM Ten Hoevel J Burhenne, et al. 2009 CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole J Clin Pharmacol 49 196 204 1:CAS:528:DC%2BD1MXisFCisrc%3D 10.1177/ 0091270008327537 19033450
28. DW Denning P Ribaud N Milpied, et al. 2002 Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis Clin Infect Dis 34 563 571 1:CAS:528:DC%2BD38XitlCitbg%3D 10.1086/324620 11807679 (Pubitemid 34165316)
29. AE Boyd S Modi SJ Howard CB Moore BG Keevil DW Denning 2004 Adverse reactions to voriconazole Clin Infect Dis 39 1241 1244 10.1086/424662 15486850 (Pubitemid 40169325)
30. M Robinson J Horn 2003 Clinical pharmacology of proton pump inhibitors: what the practicing physician needs to know Drugs 63 2739 2754 1:CAS:528:DC%2BD2cXnt1Knug%3D%3D 10.2165/00003495-200363240-00004 14664653 (Pubitemid 38049991)
31. N Wood K Tan L Purkins, et al. 2003 Effect of omeprazole on the steady-state pharmacokinetics of voriconazole Br J Clin Pharmacol 56 56 61 1:CAS:528:DC%2BD2cXjtFygsw%3D%3D 10.1046/j.1365-2125.2003.02000.x 14616415 (Pubitemid 37491735)
32. MD Levin JG den Hollander B van der Holt, et al. 2007 Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms J Antimicrob Chemother 60 1104 1107 1:CAS:528:DC%2BD2sXht1Sht77K 10.1093/jac/dkm330 17827141 (Pubitemid 47617761)
33. V Boussaud N Daudet EM Billaud, et al. 2008 Neuromuscular painful disorders: a rare side effect of voriconazole in lung transplant patients under tacrolimus J Heart Lung Transplant 27 229 232 1:STN:280:DC%2BD1c7gvVyjtA%3D%3D 10.1016/j.healun.2007.09.022 18267232 (Pubitemid 351221040)
34. A Imhof DJ Schaer U Schanz U Schwarz 2006 Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring Swiss Med Wkly 136 739 774 1:CAS:528:DC%2BD2sXhtVOisb0%3D 17183438
35. L Purkins N Wood K Greenhalgh MJ Allen SD Oliver 2003 Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety Br J Clin Pharmacol 56 10 16 1:CAS:528:DC%2BD2cXjtFyhtg%3D%3D 10.1046/j.1365-2125.2003. 01993.x 14616408 (Pubitemid 37491728)
36. K Matsumoto K Ikawa K Abematsu, et al. 2009 Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes Int J Antimicrob Agents 34 91 94 1:CAS:528:DC%2BD1MXmsVShsro%3D 10.1016/j.ijantimicag.2009.01.008 19261446